Orthogon Therapeutics LLC

Orthogon Therapeutics, LLC, based in the US, specializes in the development of antiviral drugs targeting polyomavirus infections, focusing on innovative solutions for immune-suppressed patient populations. Founded in 2012 in Canton, US, Orthogon Therapeutics, LLC is dedicated to developing antiviral therapies. The company has executed 4 deals, with its most recent funding round in December 2024 raising USD 5. 2 mn.

Orthogon Therapeutics operates independently without subsidiaries or parent companies. Orthogon Therapeutics specializes in the development of innovative antiviral drugs that target polyomavirus infections prevalent in immune-suppressed populations, such as transplant patients. The company offers a portfolio of orally administrable drugs that utilize novel mechanisms to combat BK, JC, and Merkel cell polyomaviruses. Their drug discovery platform employs advanced techniques, including 3D atomic mapping and machine learning, to improve therapeutic efficacy and is strategically focused on North American and European markets.

Orthogon Therapeutics generates revenue through partnerships with healthcare providers and pharmaceutical companies, focusing on the commercialization of its antiviral drug portfolio. The revenue model is based on B2B transactions, including licensing fees, milestone payments, and royalties from product sales. While specific pricing plans are undisclosed, the flagship drugs are expected to command premium pricing due to their innovative approaches. In December 2024, Orthogon Therapeutics raised USD 5.

2 mn in venture funding to further its research and development of therapies addressing BK virus reactivation in transplant patients. The company plans to leverage this funding to support the launch of upcoming antiviral products and expand its reach into new markets, specifically targeting increased presence in Europe by the end of 2025.